Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
30%
Ph phase_1
7
70%

Phase Distribution

7

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
7(70.0%)
Phase 2Efficacy & side effects
3(30.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (70.0%)
Phase 23 (30.0%)

Trials by Status

withdrawn220%
completed880%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

NCT00123968
withdrawnphase_2

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

NCT00415649
withdrawnphase_2

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

NCT00498056
completedphase_1

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

NCT00124007
completedphase_2

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

NCT00125970
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00123968Phase 1

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

Completed
NCT00415649Phase 2

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

Withdrawn
NCT00498056Phase 2

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

Withdrawn
NCT00124007Phase 1

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

Completed
NCT00125970Phase 2

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

Completed
NCT00955006Phase 1

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Completed
NCT01386489Phase 1

Immune Responses to Two Experimental HIV Vaccines in Healthy Adults

Completed
NCT00109629Phase 1

"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection

Completed
NCT00089531Phase 1

Candidate HIV Vaccine

Completed
NCT00270465Phase 1

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10